Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Placebo-controlled phase 2 study of inhaled pirfenidone (AP01) in progressive pulmonary fibrosis
NL-OMON60875Phase 2Active, not recruiting
- Sponsor
- Avalyn Pharmaceuticals
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pirfenidone in pulmonary fibrosis (PF), sponsored by Avalyn Pharmaceuticals. Primary endpoint: Change from baseline in forced vital capacity at Week 52. Started Sep 2025; status: active, not recruiting.
02
Drugs
pirfenidone
03
Conditions
pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NL-OMON60875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60875.